Physician profile
Tracy A Proverbs Singh
NPI 1730321662
$4,243.61
in general payments reported to CMS, 2019-2025
43 companies · $1,129 in 2025
The $1,129 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $67.84 · 2021: $354 · 2022: $516 · 2023: $785 · 2024: $1,015 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.34 |
| Education | $231.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $696.63 | 2019-2025 | Opdivo, Eliquis |
| Novartis Pharmaceuticals Corporation | $357.47 | 2019-2024 | |
| Daiichi Sankyo INC. | $289.87 | 2019-2025 | Enhertu, Vanflyta |
| Merck Sharp & Dohme LLC | $288.54 | 2019-2025 | Keytruda, Lynparza |
| Taiho Oncology, INC. | $223.87 | 2023-2025 | |
| Mirati Therapeutics, INC. | $217.74 | 2023-2024 | Krazati |
| Array Biopharma INC | $187.31 | 2021-2025 | Braftovi, Comirnaty, Paxlovid |
| Bayer Healthcare Pharmaceuticals INC. | $172.71 | 2021-2025 | |
| Astellas Pharma US INC | $147.39 | 2023-2025 | Vyloy, Xospata |
| Janssen Biotech, INC. | $139.56 | 2021-2025 | Rybrevant |
| Exelixis INC. | $138.35 | 2022-2025 | Cabometyx |
| Seagen INC. | $131.99 | 2023-2024 | Tukysa |
| Sirtex Medical INC | $104.30 | 2023-2024 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $92.83 | 2021-2025 | Onivyde |
| Pharmacosmos Therapeutics INC. | $88.03 | 2024-2025 | Monoferric |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $81.57 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.38 | 2024-2025 | Fruzaqla |
| Amgen INC. | $64.86 | 2022-2023 | Lumakras, Vectibix, Xgeva |
| Deciphera Pharmaceuticals INC. | $63.14 | 2022-2025 | Qinlock, Romvimza |
| Astrazeneca Pharmaceuticals Lp | $61.03 | 2025 | Enhertu |
| Eisai INC. | $59.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $55.16 | 2023-2025 | Ojjaara, Jemperli |
| Lilly USA, LLC | $49.19 | 2020-2023 | Verzenio, Retevmo, Jaypirca |
| Incyte Corporation | $40.53 | 2024 | Jakafi |
| Servier Pharmaceuticals LLC | $40.39 | 2022-2023 | |
| Cumberland Pharmaceuticals, INC. | $38.30 | 2025 | Sancuso |
| Apellis Pharmaceuticals, INC. | $35.09 | 2024 | Empaveli |
| Genentech USA, INC. | $33.88 | 2024-2025 | Tecentriq |
| Beigene USA, INC. | $33.52 | 2024-2025 | Tevimbra |
| Kite Pharma, INC. | $23.78 | 2025 | Yescarta |
| Tempus Ai, INC | $23.20 | 2025 | Xt Cdx |
| Coherus Oncology, INC. | $21.86 | 2021 | |
| Aveo Pharmaceuticals, INC. | $20.10 | 2025 | |
| Tersera Therapeutics LLC | $18.95 | 2025 | Xermelo |
| Puma Biotechnology, INC. | $18.07 | 2025 | |
| Jazz Pharmaceuticals INC. | $17.19 | 2025 | |
| Beone Medicines USA, INC. | $16.53 | 2025 | Tevimbra |
| Genzyme Corporation | $15.00 | 2019 | |
| Ethicon US, LLC | $14.87 | 2019 | |
| Cti Biopharma Corp. | $14.61 | 2023 | Vonjo |
| Helsinn Therapeutics (U.S.), INC. | $14.57 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Proverbs Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.